CROSS-STANDARD public interest · Home/clinical medical device
China-to-India Medical Device Compliance Gap Matrix
AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical electromedical device documentation against India CDSCO Medical Device Rules 2017 requirements — covering CDSCO classification (Classes A–D), QMS (ISO 13485), electrical safety (IS/IEC 60601-1, IEC 62304), clinical evidence, Indian Authorized Agent and Import Licence (Form MD-14/MD-15 via SUGAM), and labelling/UDI/language obligations.
Dataset 2026-06-11
Last verified 2026-06-12
6 rows
GAP MATRIX
Compliance Gap Matrix
| Compliance item | Common China baseline | India (CDSCO) | Gap / action | Source + verification date |
|---|---|---|---|---|
| CDSCO Device Classification — Medical Device Rules 2017, Rule 4 and First Schedule | China NMPA classifies medical devices into Class I (lowest risk, filing only at provincial level), Class II (moderate risk, provincial NMPA registration with technical review), and Class III (highest risk, national NMPA registration with full clinical and technical review). Classification is determined by the NMPA Medical Device Classification Catalogue (医疗器械分类目录, last major revision 2017, with ongoing amendments). Electromedical equipment is typically Class II or III under NMPA. Both NMPA and CDSCO systems follow GHTF/IMDRF risk-based principles, but the specific catalogues and class boundaries differ.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) 医疗器械分类目录 (2017, NMPA Announcement No. 104; with subsequent amendments) 医疗器械监督管理条例 (2021, State Council Order No. 739) |
India's Medical Device Rules 2017 (MDR 2017), made under the Drugs and Cosmetics Act 1940, establish four risk-based classes: Class A (low risk), Class B (low-to-moderate risk), Class C (moderate-to-high risk), and Class D (high risk). Classification is determined under Rule 4 and the First Schedule, and mirrors IMDRF/GHTF principles. General electromedical equipment (non-implantable, non-life-sustaining) typically falls in Class B or C; life-sustaining or implantable active devices may reach Class D. The class determines whether filing or full registration is required and the applicable conformity assessment depth. All medical devices — including electromedical equipment — became subject to mandatory registration or licensing requirements under a phased rollout that extended through 2023. Note: The exact list of notified device categories has been expanded progressively by CDSCO notifications since 2021; verify current CDSCO notifications for the specific device type.Medical Device Rules 2017 (G.S.R. 317(E), Ministry of Health and Family Welfare), Rule 4 and First Schedule Drugs and Cosmetics Act 1940, Section 3(b) and related amendments for medical devices CDSCO Guidance on Device Classification and Registration (SUGAM portal — sugam.gov.in) CDSCO Medical Device Notification expanding mandatory registration (2021–2023 phased rollout notifications) |
India uses a four-class (A/B/C/D) system; China uses three classes (I/II/III). Both follow GHTF risk principles, so rough equivalences exist (A≈I, B≈II, C/D≈III), but the specific classification rules and device-type catalogues differ. A Chinese Class II NMPA registration does not automatically determine the Indian class — the manufacturer must independently apply MDR 2017 Rule 4 and the First Schedule to each specific device. Additionally, India's mandatory registration rollout has expanded the scope of notified devices progressively; always verify via CDSCO whether a specific device type is currently notified (and thus subject to mandatory import licence requirements) before export.[INFORMATIONAL ONLY] Manufacturers must independently apply MDR 2017 Rule 4 and the First Schedule to each device — NMPA class cannot be assumed equivalent. Confirm whether the specific device type is currently notified (mandatory registration scope) via CDSCO SUGAM portal before planning India market entry. Engage a qualified Indian regulatory consultant given the evolving notification scope. This is informational; seek professional regulatory advice before submission. | Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India2026-06-12 · unverified |
| Clinical and Safety Evidence — CDSCO Technical Documentation Requirements | NMPA requires clinical evaluation as part of the technical dossier for Class II and III medical device registration. Clinical evaluation can be conducted through: (a) clinical investigation conducted in China (must follow NMPA clinical investigation regulations), (b) literature review and clinical data from equivalent devices, or (c) exemption from clinical trials based on the NMPA Clinical Trial Exemption Catalogue. Risk management documentation per GB/T 42062-2022, equivalent to ISO 14971:2019 and mandatory since 2023-11-01, is required. For Class III devices (including many electromedical devices), a full clinical evaluation report is typically required. The NMPA Clinical Evaluation Technical Guidance (2021) provides detailed requirements.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) — clinical evaluation requirements 医疗器械临床评价技术指导原则 (2021, NMPA guidance) GB/T 42062-2022 (equivalent to ISO 14971:2019, mandatory since 2023-11-01) — Application of risk management to medical devices 医疗器械临床试验质量管理规范 (2016, NMPA/National Health Commission joint regulation) |
India's Medical Device Rules 2017 require applicants for import licences (Form MD-14 application → MD-15 licence) to submit a technical dossier that includes: (a) evidence of marketing authorisation or free-sale certificate from the country of origin, (b) clinical data or performance evidence demonstrating safety and efficacy appropriate to the device class, (c) risk analysis and risk management documentation (ISO 14971 is the international reference), and (d) summary of clinical investigations or equivalent scientific justification. For Class C and D devices, more substantial clinical evidence is required. CDSCO may accept clinical data from other major regulatory jurisdictions (US FDA, EU MDR, Japan PMDA) as supporting evidence; however, the adequacy of the submitted data is assessed by CDSCO on a case-by-case basis. Note: CDSCO guidance on clinical evidence requirements for imported electromedical devices continues to evolve; the exact depth of clinical dossier required for each device class and type should be verified against current CDSCO guidance at the time of application.Medical Device Rules 2017, Third Schedule — technical dossier requirements for import licence (Form MD-14) ISO 14971:2019 — Medical devices — Application of risk management to medical devices (international reference for risk management documentation) CDSCO Guidance Documents on Clinical Evidence for Medical Devices (sugam.gov.in — verify current version) Drugs and Cosmetics Act 1940 and amendments |
Both CDSCO and NMPA require clinical evidence and risk management documentation — the underlying frameworks (ISO 14971, clinical data) are conceptually similar. Key gaps: (1) CDSCO requires a free-sale certificate or marketing authorisation from the country of origin as part of the import licence application — NMPA registration itself can serve this purpose if formatted correctly; (2) Clinical data generated solely in the Chinese population may need supplementation or justification for CDSCO, depending on the device type and CDSCO guidance at time of application; (3) CDSCO's clinical evidence depth requirements by device class (A/B/C/D) do not map directly to NMPA's class-based requirements — verify current CDSCO guidance; (4) Risk management documentation must be in English (or with certified translation) for CDSCO; Chinese-language NMPA risk files require translation.[INFORMATIONAL ONLY] Chinese manufacturers should compile clinical evidence and ISO 14971 risk management documentation in English-language format suitable for CDSCO submission. NMPA registration can serve as part of the free-sale certificate evidence. Verify the current depth of clinical dossier required by CDSCO for the specific device class and type via the SUGAM portal or qualified Indian regulatory consultant before application. This is informational; seek professional regulatory advice before submission. | Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India2026-06-12 · unverified |
| Indian Authorized Agent and Import Licence — Form MD-14 / MD-15 via SUGAM | China does not require a domestic Authorized Agent or import licence in the same sense for foreign-manufactured devices sold in China — instead, the foreign manufacturer registers directly with NMPA (for Class III) or provincial NMPA (for Class II), appointing a China Agent (境内代理人) who serves as the contact for NMPA purposes and accepts service of regulatory documents. The China Agent is different from a full import licence holder: Chinese importers hold import records (进口备案) but are not required to obtain a separate import licence analogous to India's MD-15. There is no direct NMPA equivalent to the IAA's function as a single named licensee bearing full import regulatory liability.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) — China Agent (境内代理人) requirements for foreign manufacturers 医疗器械监督管理条例 (2021, State Council Order No. 739) — import regulatory framework |
Under India's Medical Device Rules 2017, a foreign manufacturer wishing to import notified medical devices into India must: (1) appoint an Indian Authorized Agent (IAA) — a resident Indian person or entity registered with CDSCO who acts as the local representative and accepts regulatory responsibility in India; (2) apply for an Import Licence via Form MD-14 through the SUGAM online portal (sugam.gov.in), which, if approved, results in the issuance of Form MD-15 (Import Licence). The IAA's registration and CDSCO-recognised Indian address are mandatory for the MD-14 application. The import licence is device-specific (covers specified product(s), manufacturer, and IAA) and must be renewed periodically. The IAA bears liability for the device in the Indian market in a manner analogous to the EU Authorised Representative. Note: The SUGAM portal and associated workflow have been updated multiple times since 2021 — verify current application requirements directly on sugam.gov.in.Medical Device Rules 2017, Rule 21 — Import Licence requirements for medical devices Medical Device Rules 2017, Form MD-14 (Import Licence Application) and Form MD-15 (Import Licence) Medical Device Rules 2017, Rule 3 — Definition of Indian Authorized Agent CDSCO SUGAM Portal — sugam.gov.in (online application system for import licence) |
This is a major structural gap with no direct Chinese equivalent. India requires: (1) appointment of a CDSCO-registered Indian Authorized Agent before any import licence application can proceed — this is a new relationship to establish from scratch for a Chinese manufacturer; (2) application through the SUGAM portal using Form MD-14, submitting the full technical dossier, QMS evidence, clinical data, and IAA appointment details; (3) receipt of Form MD-15 (Import Licence) before commercial importation of the notified device can legally occur. Timeline for CDSCO import licence review has historically been 6–18 months depending on device class and dossier completeness — verify current CDSCO processing times. The IAA bears ongoing post-market surveillance and recall obligations in India.[INFORMATIONAL ONLY] Appointing an Indian Authorized Agent and obtaining Form MD-15 via the SUGAM portal are non-negotiable prerequisites for importing notified medical devices into India — there is no equivalent in the Chinese regulatory framework. Chinese manufacturers must identify and appoint a CDSCO-registered IAA before beginning the import licence application process. Plan for a 6–18 month review period. The IAA carries ongoing post-market obligations. This is informational; engage a qualified Indian regulatory consultant and legal adviser before proceeding. | CDSCO SUGAM Portal — Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare, Government of India2026-06-12 · unverified |
| Labelling, UDI, and Language Requirements — India MDR 2017 | China's labelling requirements for medical devices are set under the Medical Device Instructions for Use and Label Management Regulations (医疗器械说明书和标签管理规定, NMPA Order No. 6, 2014, partially superseded by 2022 updates). Mandatory elements include device name; model and specification; manufacturer name, address, and contact; registration or filing number; production date and expiry/use-by date; batch number; intended use; instructions for use; safety warnings; storage conditions; and for electromedical devices, electrical safety parameters. Labels must be in simplified Chinese; multi-language labels are permitted provided Chinese content is clear and prominent. China has implemented a medical device UDI system (国家医疗器械唯一标识系统, NMPA national UDI database) with mandatory UDI for Class III devices from 2021, Class II from 2023, and Class I from 2025 (phased rollout). UDI consists of Device Identifier (DI) + Production Identifier (PI).医疗器械说明书和标签管理规定 (NMPA Order No. 6, 2014; 2022 updates) 国家医疗器械唯一标识系统 (National UDI system — NMPA, phased mandatory rollout 2021–2025) 医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) — labelling requirements in registration dossier |
India's Medical Device Rules 2017 (Fourth Schedule) prescribe mandatory labelling requirements for medical devices sold or imported into India. Required label elements include: device name; manufacturer name and address; name and address of the Indian Authorized Agent (IAA) / importer; batch or lot number; manufacturing date; expiry or use-by date (where applicable); net contents and quantity; instructions for use (IFU); storage conditions; warnings and precautions; and for electromedical devices, electrical safety information (voltage, frequency, power, protection class). English is the mandatory language for labelling in India; bilingual labels (English + regional language) may be used but English must be legible. A Unique Device Identification (UDI) system for India is under development by CDSCO — as of mid-2026, a mandatory UDI requirement for imported devices has not been fully rolled out, but manufacturers should monitor CDSCO notifications as the framework is expected to be implemented progressively. Note: CDSCO has been aligning India's UDI approach with international IMDRF UDI guidelines — verify current CDSCO notifications for UDI status at time of application.Medical Device Rules 2017, Fourth Schedule — Labelling Requirements for Medical Devices Medical Device Rules 2017, Rule 11 — Labelling requirements and language CDSCO Guidance on Unique Device Identification (UDI) — IMDRF UDI guidance alignment (verify current CDSCO notifications at sugam.gov.in) Drugs and Cosmetics Act 1940, labelling provisions as amended for medical devices |
Key labelling gaps for China-to-India export: (1) Language — Chinese labels use simplified Chinese as the mandatory language; India requires English. All Chinese-language label content (including IFU) must be fully reproduced in English for the Indian market; (2) Indian Authorized Agent address — India mandates the IAA's name and Indian address on the label; Chinese labels typically show the domestic China Agent or Chinese manufacturer address only; Indian market-specific labels must add the IAA details; (3) NMPA registration number on Chinese labels is not required on Indian labels and should not be confused with CDSCO import licence number; (4) UDI — China has a mandatory UDI system; India's UDI rollout is still in progress as of mid-2026. Chinese manufacturers with UDI compliance may have a head-start but must monitor CDSCO UDI notifications for India-specific requirements; (5) Regional India labelling norms (BIS hazard pictograms, India electrical safety standards symbols) must be applied as relevant.[INFORMATIONAL ONLY] Chinese manufacturers must create India-market-specific English-language labels and IFU, incorporating the Indian Authorized Agent name and Indian address as required by MDR 2017 Fourth Schedule. Chinese-language labels and NMPA registration numbers cannot be used as-is for the Indian market. Monitor CDSCO UDI notifications for India-specific UDI requirements as the rollout progresses. Verify current CDSCO labelling guidance via SUGAM portal or a qualified Indian regulatory consultant. This is informational; seek professional regulatory advice before submission. | Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India2026-06-12 · unverified |
| Quality Management System — ISO 13485 under India MDR 2017 | China requires QMS compliance for Class II and III medical device registration under NMPA Order No. 47 (2021). The relevant standard is YY/T 0287-2017 (equivalent to ISO 13485:2016). QMS certification is assessed by NMPA-authorised inspection bodies, and a Medical Device GMP certificate (医疗器械生产质量管理规范, GMP) issued by the provincial or national NMPA is required. The GMP certificate and ISO 13485 certificate (if held) are commonly included in technical dossiers. Because ISO 13485 is also accepted by CDSCO, a Chinese manufacturer holding an internationally recognised ISO 13485 certificate may be able to use this for the Indian application, subject to CDSCO acceptance at the time of filing.YY/T 0287-2017 (equivalent to ISO 13485:2016) — Medical Devices Quality Management Systems 医疗器械生产质量管理规范 (GMP for Medical Devices, NMPA Order No. 64, 2014; NMPA Order No. 107 issued Nov 2025, effective Nov 2026) 医疗器械注册与备案管理办法 (2021, NMPA Order No. 47) |
India's Medical Device Rules 2017 require manufacturers (including foreign manufacturers applying for import licences) to demonstrate compliance with a Quality Management System (QMS) as a condition for device registration and import licensing. ISO 13485:2016 (Medical devices — Quality management systems — Requirements for regulatory purposes) is the expected international standard. For import licence applications (Form MD-14/MD-15), the foreign manufacturer must provide evidence of QMS certification or compliance, typically an ISO 13485 certificate from a NABH-accredited or internationally recognised certification body. CDSCO may also accept equivalent national QMS standards from the country of manufacture if recognised. Note: CDSCO guidance documents and application requirements continue to evolve — verify current SUGAM portal requirements for the specific application type.Medical Device Rules 2017 (G.S.R. 317(E)), Third Schedule — requirements for import licences including QMS evidence ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes CDSCO Guidance on Import Licence Application via SUGAM portal (sugam.gov.in) |
Both India and China accept ISO 13485 as the QMS standard, which is a meaningful alignment. The primary gap is procedural: the ISO 13485 certificate must be presented to CDSCO in a specific format through the SUGAM portal, and the issuing certification body must be internationally recognised. A Chinese NMPA GMP certificate alone (without an internationally recognised ISO 13485 certificate) may not satisfy CDSCO requirements — verify current CDSCO acceptance criteria. Additionally, the QMS scope must cover the specific device types being imported into India.[INFORMATIONAL ONLY] A Chinese manufacturer holding a valid, internationally recognised ISO 13485 certificate covering the relevant device types has a significant head-start for the Indian QMS requirement. However, the certificate must be presented in CDSCO-required format through the SUGAM portal and the issuing body must be internationally recognised. Confirm current CDSCO requirements with a qualified Indian regulatory consultant before filing. This is informational; seek professional regulatory advice before submission. | Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India2026-06-12 · unverified |
| Electromedical Safety — IS 13450:2024 and IEC 62304 (India) | China's GB 9706.1-2020 (mandatory from 2023-05-01) is aligned to IEC 60601-1 Ed.3 with minor Chinese deviations, covering general requirements for basic safety and essential performance of medical electrical equipment. For software, YY/T 0664-2020 (equivalent to IEC 62304:2006+AMD1:2015) is the applicable standard for medical device software lifecycle processes, referenced in NMPA registration technical review guidelines. GB 9706.1-2020 and IS 13450:2024 both derive from the IEC 60601-1 family, providing substantial test-data alignment, but India now cites IS 13450:2024 as identical to IEC 60601-1 Ed.3.2. Separate test reports to the applicable national standard are required by each regulator.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01) YY/T 0664-2020 — Medical device software — Software life cycle processes (equivalent to IEC 62304:2006+AMD1:2015) NMPA Technical Review Guidelines for Medical Electrical Equipment Safety |
India has adopted IS 13450:2024, identical to IEC 60601-1 Ed.3.2, as the national standard for general requirements for basic safety and essential performance of medical electrical equipment, published by the Bureau of Indian Standards (BIS). Test reports to IS 13450:2024 from a BIS-recognised or internationally accredited laboratory are expected as part of the technical documentation for CDSCO import licence applications. Device-type-specific standards (IS/IEC 60601-2-x series) apply where adopted by BIS. For medical devices containing software, IEC 62304 (Medical device software — Software life cycle processes) is referenced in CDSCO guidance as the relevant standard for software lifecycle management and risk control. Note: BIS adoption status and CDSCO-specific test report requirements should be verified for the exact device type and current CDSCO guidance, as the regulatory framework for electromedical devices in India is still developing.IS 13450:2024 (Bureau of Indian Standards, identical to IEC 60601-1 Ed.3.2) — Medical electrical equipment — General requirements for basic safety and essential performance IEC 62304:2006+AMD1:2015 — Medical device software — Software life cycle processes (referenced in CDSCO guidance) Medical Device Rules 2017, Third Schedule — technical documentation requirements for import licence Bureau of Indian Standards (BIS) — IS/IEC standards adoption list (bis.gov.in) |
IS 13450:2024 is identical to IEC 60601-1 Ed.3.2, while GB 9706.1-2020 aligns to IEC 60601-1 Ed.3 with Chinese deviations. The physical safety test parameters (leakage current, dielectric withstand, insulation, creepage, clearance) still overlap substantially, offering a strong foundation for test data reuse. Key gaps: (1) CDSCO requires test reports referencing IS 13450:2024 specifically; Chinese GB 9706.1-2020 reports alone may not be accepted without confirmation from the lab and CDSCO; (2) Applicable IS/IEC 60601-2-x particular standards must be verified for BIS adoption status — some may lag or differ from Chinese YY/T equivalents; (3) For software-containing devices, IEC 62304 compliance documentation must be demonstrated — Chinese YY/T 0664-2020 reports are closely equivalent but the documentation format may need adaptation for CDSCO; (4) India's regulatory guidance for electromedical software (IEC 62304) is still developing — flag uncertainty and verify with CDSCO current guidance.[INFORMATIONAL ONLY] A device already certified to GB 9706.1-2020 has a strong technical foundation for IS 13450:2024 compliance given their shared IEC 60601-1 basis, but IS 13450:2024 is identical to IEC 60601-1 Ed.3.2 and should be cited directly for India. Verify with a BIS-accredited or ILAC-MRA laboratory whether existing test data can be leveraged for IS 13450:2024 reports acceptable to CDSCO. For software-containing devices, prepare IEC 62304 lifecycle documentation referencing YY/T 0664-2020 compliance. The Indian electromedical regulatory framework is still developing — verify current CDSCO guidance before submission. This is informational; seek professional regulatory advice. | Bureau of Indian Standards (BIS); CDSCO — Medical Device Rules 2017 technical documentation requirements2026-06-12 · unverified |
E-E-A-T
Named editorial review
Pending named reviewer
Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.
Editorial controlsRows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.
SOURCES
Official-source register.
- Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India · accessed 2026-06-12 · unverified · used in 4 rows
- CDSCO SUGAM Portal — Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare, Government of India · accessed 2026-06-12 · unverified · used in 1 rows
- Bureau of Indian Standards (BIS); CDSCO — Medical Device Rules 2017 technical documentation requirements · accessed 2026-06-12 · unverified · used in 1 rows